Living with CML can be challenging. Fortunately, these advances in CML treatment offer hope beyond daily pills.

Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will ...

The latter also had serious side effects and, moreover, was not a cure but merely a way to prolong survival. Thus, before Gleevec, only 30% of patients with CML survived for even five years after ...

Alternating between Glivec and Stivarga therapy didn't impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST.

and reduce imatinib binding either as a result of changes to amino-acid side-chains, which contribute favourable lipophilic contacts or hydrogen-bond (H-bond) interactions, or as a result of ...